Carfilzomib: In relapsed, or relapsed and refractory, multiple myeloma

Drugs

Volumn 72, Issue 15, 2012, Pages 2023-2032

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Carfilzomib; Multiple myeloma; Myeloma

Indexed keywords

CARFILZOMIB; ONO 7057; UNCLASSIFIED DRUG;

ANEMIA; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; MULTIPLE MYELOMA; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84867317695     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209010-000000000-00000     Document Type: Article

References (28)

1. The Merck Manual: multiple myeloma [online]. Available from URL: http://www.merckmanuals.com/professional/hematology-and-oncology/plasma cell-disorders/multiple myeloma.html [Accessed 2012 Sep 11]
2. American Cancer Society. Multiple myeloma [online]. Available from URL: http://www.cancer.org/Cancer/Multi pleMyeloma/DetailedGuide/multiple-myeloma- key-statistics [Accessed 2012 Sep 11]
3. Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2010; 2010: 303-9
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 Mar 1; 111 (5): 2516-20
5. Baumeister W, Walz J, Zü hl F, et al. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998 Feb 6; 92 (3): 367-80 (Pubitemid 28093014)
6. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007 Jul 1; 67 (13): 6383-91 (Pubitemid 47037522)
7. Fuchs O, Provaznikova D, Marinov I, et al. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc Hematol Disord Drug Targets 2009 Mar; 9 (1): 62-77
8. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011 May 1; 17 (9): 2734-43
9. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitinproteasome pathway, against preclinical models of multiple myeloma. Blood 2007 Nov 1; 110 (9): 3281-90 (Pubitemid 350106321)
10. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010 Jul; 51 (7): 1178-87
11. US FDA. Kyprolis (carfilzomib) for injection: US prescribing information [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda docs/label/2012/202714lbl.pdf [Accessed 2012 Sep 11]
12. Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009 Oct 15; 114 (16): 3439-47
13. Alsina M, Trudel S, Furman RR, et al. A phase 1 singleagent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. Epub 2012 Jul 3
14. Onyx Pharmaceuticals Inc. NDA 202714, Onyx Pharmaceuticals Inc., proposed trade name: Kyprolis (carfilzomib for injection), briefing document [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvi soryCommittee/UCM308565.pdf [Accessed 2012 Sep 11]
15. O'Connor OA, Stewart AK, Vallone M, et al. Aphase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009 Nov 15; 15 (22): 7085-91
16. Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011 Oct; 39 (10): 1873-82
17. Niesvizky R, Vij R, Martin T, et al. Carfilzomib pharmacokinetics, safety, and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: final results [abstract no. 0890]. Haematologica 2011 Jun; 96 Suppl. 2: 370-1
18. Jagannath S, Vij R, Stewart K, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract no. 8504]. J Clin Oncol 2009 May 20; 27 (15 Suppl.)
19. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. Epub 2012 Jul 25
20. Vij R, Siegel DS, Jagannath S, et al. An open-label, singlearm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. Epub 2012 Jul 30
21. Vij R, Wang M, Kaufman JL, et al. An open-label, singlearm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012 Jun 14; 119 (24): 5661-70
22. US FDA. New Drug Application (NDA) 202714, carfilzomib (Kyprolis): Food and Drug Administration briefing document, Oncologic Drugs Advisory Committee Meeting, June 20, 2012 [online]. Available from URL: http://www.fda.gov/ downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommi ttee/UCM308563.pdf [Accessed 2012 Sep 11]
23. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 Sep; 20 (9): 1467-73 (Pubitemid 44264086)
24. Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007 [abstract no. 2930]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 10-13; San Diego (CA)
25. Siegel D, Kaufman JL, Wang M, et al. A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R Mm) [abstract no. 0302]. 16th Congress of the European Hematology Association; 2011 Jun 9-12; London
26. US FDA. Transcript of the Oncologic Drugs Advisory Committee discussion of the New Drug Application, 202714, with the proposed trade name Kyprolis, carfilzomib, for injection [online]. Available from URL: http://www.fda.gov/ downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommi ttee/UCM314709.pdf [Accessed 2012 Sep 11]
27. Nooka A, Badros A, Patel P, et al. Hematologic safety data of single-agent carfilzomib in relapsed and/or refractory multiple myeloma: pooled data from four phase 2 studies [abstract no. 8086]. J Clin Oncol 2012 May 30; 30 (15 Suppl.)
28. Harvey RD, Lonial S, Patel P, et al. Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [abstract no. 0844]. Haematologica 2012 Jun 1; 97 Suppl. 1: 346